CIRM Funded Clinical Trials
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 and Advancing ISP-001 for Mucopolysaccharidosis I: Clinical Expansion, Clinical Manufacturing and Release Testing
Disease Area:
Bone or Cartilage Disease, Genetic Disorder, Hearing Loss, Intellectual Disability, Metabolic Disorders, Other, Pediatrics, Vision Loss
Trial Sponsor:
Immusoft of CA, Inc.
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
ClinicalTrials.gov ID: